DNLI
Denali·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Stock Price Surged Significantly
Consensus Rating "Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About DNLI
Denali Therapeutics Inc.
A biopharmaceutical company that develops a broad portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases
Biological Technology
--
12/08/2017
NASDAQ Stock Exchange
422
12-31
Common stock
161 Oyster Point Blvd, South San Francisco, CA, 94080
--
Denali Therapeutics Inc., was incorporated in Delaware in October 2013. Their goal is to discover and develop treatments to defeat degenerative problems. Neurodegeneration represents one of the most important unmet medical needs of their era, such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or ALS, and other neurodegenerative diseases. The burden of these diseases on patients and society is enormous. They believe now is the right time for them to use their strong and ambitious efforts to defeat neurodegeneration. They believe that they can achieve success in a field with little success because of their rich experience of success, dedicated team of scientists and drug developers, their focused scientific strategy, and their proprietary blood-brain barrier (BBB) platform delivery technology. They are developing a broad portfolio of targeted therapy candidates for neurodegenerative diseases and recently started their first clinical trial. They started operations in May 2015.
Company Financials
EPS
DNLI has released its 2025 Q3 earnings. EPS was reported at -0.74, versus the expected -0.76, beating expectations. The chart below visualizes how DNLI has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
